Listar por tema "Schizophrenia"
Mostrando ítems 1-17 de 17
-
Antipsychotic dose reduction compared to dose continuation for people with schizophrenia
(2022)Background: Antipsychotic drugs are the mainstay treatment for schizophrenia, yet they are associated with diverse and potentially dose-related side effects which can reduce quality of life. For this reason, the lowest ... -
Antipsychotic polypharmacy reduction versus polypharmacy continuation for people with schizophrenia
(2022)Background: In clinical practice, different antipsychotics can be combined in the treatment of people with schizophrenia (polypharmacy). This strategy can aim at increasing efficacy, but might also increase the adverse ... -
Clozapine associated with autoimmune reaction, fever and low level cardiotoxicity - a case report
(2017)Background: Clozapine is a second-generation antipsychotic drug used in treatment-resistant schizophrenia. Fever induced by clozapine is a rather frequent side-effect which usually occurs in the first 4 weeks of treatment. ... -
Constituents of saffron (Crocus sativus L.) as potential candidates for the treatment of anxiety disorders and schizophrenia
(2016)Anxiety disorders and schizophrenia are common public health issues. The dried stigma of the plant Crocus sativus L., (C. sativus) commonly known as saffron are used in folk medicine for various purposes. Several lines of ... -
Crocins, the active constituents of Crocus sativus L., counteracted apomorphine-induced performance deficits in the novel object recognition task, but not novel object location task, in rats
(2017)Schizophrenia is a chronic mental disease that affects nearly 1% of the population worldwide. Several lines of evidence suggest that the dopaminergic (DAergic) system might be compromised in schizophrenia. Specifically, ... -
Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats
(2014)Experimental evidence indicates that the non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist ketamine impairs cognition and can mimic certain aspects of positive and negative symptoms of schizophrenia in rodents. ... -
Crocus sativus L. extracts and its constituents crocins and safranal; Potential candidates for schizophrenia treatment?
(2021)Schizophrenia is a chronic mental devastating disease. Current therapy suffers from various limitations including low efficacy and serious side effects. Thus, there is an urgent necessity to develop new antipsychotics with ... -
Do patients with schizophrenia have higher infection and mortality rates due to COVID-19? A systematic review
(2021)People with mental illness are known to have poorer physical health outcomes. Among them, patients with schizophrenia spectrum disorders are disproportionately burdened. A number of recent studies have highlighted that ... -
Effects of the inducible nitric oxide synthase inhibitor aminoguanidine in two different rat models of schizophrenia
(2016)Several lines evidence indicate that the non-competitive N-methyl-d-aspartate (NMDA) receptor antagonist ketamine and the mixed dopamine (DA) D1/D2 receptor agonist apomorphine induce schizophrenia-like symptoms in rodents, ... -
Evidence for genetic contribution to the increased risk of type 2 diabetes in schizophrenia
(2018)The epidemiologic link between schizophrenia (SCZ) and type 2 diabetes (T2D) remains poorly understood. Here, we investigate the presence and extent of a shared genetic background between SCZ and T2D using genome-wide ... -
A meta-analysis of FZD3 gene polymorphisms and their association with schizophrenia
(2016)Objective The aim of this study was to investigate the potential association of FZD3 polymorphisms with schizophrenia. Methods A systematic review and a meta-analysis were carried out comprising of nine genetic association ... -
The nitric oxide (No) donor sodium nitroprusside (snp) and its potential for the schizophrenia therapy: Lights and shadows
(2021)Schizophrenia is a severe psychiatric disorder affecting up to 1% of the worldwide popula-tion. Available therapy presents different limits comprising lack of efficiency in attenuating negative symptoms and cognitive ... -
The novel dehydroepiandrosterone (DHEA) derivative BNN27 counteracts cognitive deficits induced by the D1/D2 dopaminergic receptor agonist apomorphine in rats
(2021)Rationale: Schizophrenia is a devastating mental disease that affects nearly 1% of the population worldwide. It is well documented that the dopaminergic (DAergic) system is compromised in schizophrenia. It is of note that ... -
The response of subgroups of patients with schizophrenia to different antipsychotic drugs: a systematic review and meta-analysis
(2022)Background: As comparatively few trials in subgroups of patients with schizophrenia have been done, clinicians need to know whether they can rely on the results of randomised controlled trials (RCTs) in the general population ... -
The role of nitric oxide donors in schizophrenia: Basic studies and clinical applications
(2015)Schizophrenia is a complex and chronic mental health disease that affects nearly 1% of the population worldwide. While the current antipsychotic medications have profoundly impacted the treatment of schizophrenia over the ... -
The role of nitric oxide synthase inhibitors in schizophrenia
(2016)Close to 1% of the world population suffer from schizophrenia. Current medications for this chronic mental disorder have greatly improved treatment over the last half century or more, but, the newer atypical antipsychotics ... -
SELF-DESTRUCTIVE BEHAVIOR IN PATIENTS WITH SCHIZOPHRENIA SPECTRUM DISORDERS. FEATURES OF PATHOGENESIS AND PATHODYNAMICS
(2022)OBJECTIVE: The aim: To prove the heterogeneity of pathogenetic mechanisms and pathodynamics of self-destructive behaviour (SdB) in patients with schizophrenia spectrum disorders (SSD). PATIENTS AND METHODS: Materials and ...